-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On body mass index (BMI) of venous thrombosis in patients with clinical embolism (VTE) affect the outcome of information is more limited
.
Recently, a research article was published in the Journal of Thrombosis and Haemostasis, the authoritative journal of thrombosis and coagulation diseases, which aims to investigate the influence of BMI on the baseline characteristics, treatment mode and 24-month outcome of VTE patients
thrombus
GARFIELD-VTE is a prospective, non-interventional study that included 10869 patients with objectively diagnosed VTE
.
Patients were grouped according to BMI: <18.
5 (low weight; n=214); 18.
Compared with patients with normal BMI, obese patients are more often taking anticoagulants for ≥2 years (52.
3% vs.
37.
7%)
.
After 24 months, the risk of all-cause death in overweight and obese patients was lower than that of patients with normal BMI (adjusted hazard ratio [95%CI] was 0.
VTE patients who are underweight have the highest risk of death and major bleeding
Original Source: Influence of Body Mass Index ON Venous Thromboembolism in Clinical Outcomes: Insights from GARFIELD-VTE in this message